Updates are available Correction dated 2022-03-11
Click to view Correction: https://doi.org/10.1038/s41416-022-01781-y
-
Authors
Rose, Tracy L.
Weir, William H.
Mayhew, Gregory M.
Shibata, Yoichiro
Eulitt, Patrick
Uronis, Joshua M.
Zhou, Mi
Nielsen, Matthew
Smith, Angela B.
Woods, Michael
Hayward, Michele C.
Salazar, Ashley H.
Milowsky, Matthew I.
Wobker, Sara E.
McGinty, Katrina
Millburn, Michael V.
Eisner, Joel R.
Kim, William Y. http://orcid.org/0000-0001-7922-2156
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K12CA120780, K08CA24896)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Doris Duke Charitable Foundation (2015213)
University Cancer Research Fund, GeneCentric Therapeutics
- License Information
-
More Information
Article History
Received: 3 December 2020
Revised: 7 June 2021
Accepted: 1 July 2021
First Online: 22 July 2021
Ethics approval and consent to participate
: This study was reviewed and approved by the Institutional Review Board at UNC with an approved IRB 18-1478. All patient data were de-identified at the time of data abstraction from the electronic medical record. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable. No individual patient data are included in the publication.
: This work was funded in part through a research collaboration agreement between Janssen Research & Development, LLC and GeneCentric Therapeutics, Inc. and a sponsored research agreement between GeneCentric Therapeutics, Inc and the University of North Carolina at Chapel Hill. TLR is supported by the Doris Duke Charitable Foundation (grant number 2015213) and the National Cancer Institute of the National Institutes of Health (1K08CA248967-01 Clinical Investigator Award). WYK and TLR receive research funding from GeneCentric Therapeutics and Merck. TLR receives research funding from Genentech/Hoffman-La Roche and Bristol-Myers Squibb. GMM, YS, MVM, JMU and JRE are employees of GeneCentric Therapeutics, Inc. and have stock interest in the company. GM a patent holder of the GeneCentric bladder cancer subtype classifier.
